Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jessie Wang's publication output changed over time?
ScholarIQpublication output · 2011–2021
Output grew0% over the shown period — from 1 works in 2011 to 1 in 2021.
1
3
2
2
1
1
1
2011201320142015201620192021
What are the most-cited papers on Jessie Wang?
ScholarIQmost cited works
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
Xiaoli Wang, Giridhar Tirucherai, Thomas Marbury, Jessie Wang, Ming Chang, Donglu Zhang, Yan Song, Janice Pursley, Rebecca A. Boyd, Charles Frost
The Journal of Clinical Pharmacology. 2015285 CitationsOPEN ACCESS
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor<scp>X</scp>a inhibitor, in healthy subjects
Charles Frost, Sunil Nepal, Jessie Wang, Alan Schuster, Wonkyung Byon, Rebecca A. Boyd, Zhigang Yu, Andrew Shenker, Yu Chen Barrett, Rogelio Mosqueda‐Garcia, Frank LaCreta
S13842274. 2013283 CitationsOPEN ACCESS
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay Upreti, Jessie Wang, Yu Chen Barrett, Wonkyung Byon, Rebecca A. Boyd, Janice Pursley, Frank LaCreta, Charles Frost
S13842274. 2013271 CitationsOPEN ACCESS
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Ming Chang, Zhigang Yu, Andrew Shenker, Jessie Wang, Janice Pursley, Wonkyung Byon, Rebecca A. Boyd, Frank LaCreta, Charles Frost
The Journal of Clinical Pharmacology. 2015173 Citations
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
Jeffrey S. Hyams, Sonia Thomas, Nathan Gotman, Yael Haberman, Rebekah Karns, Melanie Schirmer, Angela Mo, David R. Mack, Brendan Boyle, Anne M. Griffiths, Neal S. LeLeiko, Cary G. Sauer, David J. Keljo, James Markowitz, Susan S. Baker, Joel R. Rosh, Robert N. Baldassano, Ashish Patel, Marian Pfefferkorn, Anthony Otley, Melvin B. Heyman, Joshua D. Noe, Maria Oliva‐Hemker, Paul A. Rufo, Jennifer Strople, David Ziring, Stephen L. Guthery, Boris Sudel, Keith Benkov, Prateek Wali, Dedrick E. Moulton, Jonathan Evans, Michael D. Kappelman, Miriam Marquis, Francisco Sylvester, Margaret H. Collins, Suresh Venkateswaran, Marla Dubinsky, Vin Tangpricha, Krista Spada, Bradley Saul, Jessie Wang, José Serrano, Kevin A. Hommel, Urko M. Marigorta, Greg Gibson, Ramnik J. Xavier, Subra Kugathasan, Thomas D. Walters, Lee A. Denson
The Lancet. 2019168 CitationsOPEN ACCESS
Related on ScholarIQ
Angiocrine Bioscience (United States)
Institution
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end‐stage renal disease on hemodialysis
Paper
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor<scp>X</scp>a inhibitor, in healthy subjects
Paper
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Paper
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Paper
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
Paper